富瑞料蘋果(AAPL.US)iPhone今年在華銷量有雙位數跌幅
富瑞發表報告,稱蘋果(AAPL.US)iPhone在中國的銷量跌幅不斷擴大,預計今年銷量可能會進一步下降。
報告引述行業調查提到,蘋果最新iPhone去年在中國的銷售開局異常低迷,近期按年跌幅擴大至30%,去年12月蘋果銷量出現雙位數跌幅,相反其他手機製造商皆出現增長,特別是華為,估計去年華為手機出貨量將達到3,500萬部。
富瑞稱,預計今年iPhone亦會繼續有雙位數的跌幅,上周各個網上平台增加iPhone的減價幅度,但仍然未能刺激銷售增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.